Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

Figure 1

Case #1 of a 71-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c), within 3 months after completion of Radium-223 (d, e, f), and 6–12 months after Radium-223 (g, h, i). Imaging findings are summarized in Table 1.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)